Literature DB >> 18991674

Physiological basis for contractile dysfunction in heart failure.

Luciano Dalla Libera1, Giorgio Vescovo, Maurizio Volterrani.   

Abstract

The purpose of this review is to enlighten the mechanisms of skeletal muscle dysfunction in heart failure. The muscle hypothesis suggests that chronic heart failure (CHF) symptoms, dyspnoea and fatigue are due to skeletal muscle alterations. Hyperventilation due to altered ergoreflex seems to be the cause of shortness of breath. Qualitative and quantitative changes occurring in the skeletal muscle, such as muscle wastage and shift from slow to fast fibers type, are likely to be responsible for fatigue. Mechanisms leading to muscle wastage in chronic heart failure, include cytokine-triggered skeletal muscle apoptosis, but also ubiquitin/proteasome and non-ubiquitin-dependent pathways. The regulation of fibre type involves the growth hormone/insulin-like growth factor 1/calcineurin/ transcriptional coactivator PGC1 cascade. The imbalance between protein synthesis and degradation plays an important role. Protein degradation can occur through ubiquitin-dependent and non-ubiquit-independent pathways. Systems controlling ubiquitin/ proteasome activation have been described. These are triggered by tumour necrosis factor and growth hormone/ insulin-like growth factor 1. However, an important role is played by apoptosis. In humans, and experimental models of heart failure, programmed cell death has been found in skeletal muscle and interstitial cells. Apoptosis is triggered by tumour necrosis factor and in vitro experiments have shown that it can be induced by its second messenger sphingosine. Apoptosis correlates with the severity of the heart failure syndrome. It involves activation of caspases 3 and 9 and mitochondrial cytochrome c release. Sarcomeric protein oxidation and its consequent contractile impairment can form another cause of skeletal muscle dysfunction in CHF.

Entities:  

Mesh:

Year:  2008        PMID: 18991674     DOI: 10.2174/138161208786071254

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  5 in total

Review 1.  Sphingolipid metabolism, oxidant signaling, and contractile function of skeletal muscle.

Authors:  Mariana N Nikolova-Karakashian; Michael B Reid
Journal:  Antioxid Redox Signal       Date:  2011-06-08       Impact factor: 8.401

2.  Diclofenac, a Non-steroidal Anti-inflammatory Drug, Inhibits L-type Ca Channels in Neonatal Rat Ventricular Cardiomyocytes.

Authors:  Oleg V Yarishkin; Eun Mi Hwang; Donggyu Kim; Jae Cheal Yoo; Sang Soo Kang; Deok Ryoung Kim; Jae-Hee-Jung Shin; Hye-Joo Chung; Ho-Sang Jeong; Dawon Kang; Jaehee Han; Jae-Yong Park; Seong-Geun Hong
Journal:  Korean J Physiol Pharmacol       Date:  2009-12-31       Impact factor: 2.016

3.  Validity of anaerobic threshold measured in resistance exercise.

Authors:  Takayuki Masuda; Shinta Takeuchi; Yusuke Kubo; Yusuke Nishida
Journal:  J Phys Ther Sci       Date:  2022-03-14

Review 4.  Abnormalities of Skeletal Muscle, Adipocyte Tissue, and Lipid Metabolism in Heart Failure: Practical Therapeutic Targets.

Authors:  Shingo Takada; Hisataka Sabe; Shintaro Kinugawa
Journal:  Front Cardiovasc Med       Date:  2020-05-12

5.  Effects of endurance exercise and doxorubicin on skeletal muscle myogenic regulatory factor expression.

Authors:  Colin J Quinn; David S Hydock
Journal:  Muscles Ligaments Tendons J       Date:  2018-01-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.